Core Viewpoint - The acquisition of Orbital Therapeutics by Bristol-Myers Squibb for $1.5 billion in cash aims to enhance the company's CAR T cell immunotherapy product portfolio, particularly focusing on the candidate drug OTX-201 for autoimmune diseases [1] Group 1 - Bristol-Myers Squibb is acquiring privately held Orbital Therapeutics for $1.5 billion in cash [1] - The acquisition will expand Bristol-Myers Squibb's CAR T cell immunotherapy offerings [1] - OTX-201, a key experimental candidate from Orbital, targets autoimmune diseases [1]